The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity?

Affiliations

Editorial

David A Waller. J Thorac Dis. 2018 Apr.

. 2018 Apr;10(Suppl 9):S1044-S1046.

doi: 10.21037/jtd.2018.04.63.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
Saddoughi SA, Abdelsattar ZM, Blackmon SH. Saddoughi SA, et al. Ann Thorac Surg. 2018 Feb;105(2):432-437. doi: 10.1016/j.athoracsur.2017.09.036. Epub 2017 Dec 7. Ann Thorac Surg. 2018. PMID: 29223422

1. Saddoughi SA, Abdelsattar ZM, Blackmon SH. National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. Ann Thorac Surg 2018;105:432-7. 10.1016/j.athoracsur.2017.09.036 - DOI - PubMed
1. Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 2016;8:743-50. 10.2147/CLEP.S105396 - DOI - PMC - PubMed
1. Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients. PLoS One 2015;10:e0145039. 10.1371/journal.pone.0145039 - DOI - PMC - PubMed
1. Rusch VW. Trials in malignant mesothelioma. LCSG 851 and 882. Chest 1994;106:359S-62S. - PubMed
1. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006;24:1561-7. 10.1200/JCO.2005.04.6813 - DOI - PubMed